A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis ; volume:8 ; number:1 ; day:10 ; month:1 ; year:2018 ; pages:1-15 ; date:12.2018
Scientific reports ; 8, Heft 1 (10.1.2018), 1-15, 12.2018

Schlagwort
Atemwegskrankheit
Atemnot

Urheber
Roach, Katy M.
Beteiligte Personen und Organisationen
Sutcliffe, Amanda
Matthews, Laura
Elliott, Gill
Newby, Chris
Amrani, Yassine
Bradding, Peter
SpringerLink (Online service)

DOI
10.1038/s41598-017-18555-9
URN
urn:nbn:de:1111-201804059279
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:02 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Roach, Katy M.
  • Sutcliffe, Amanda
  • Matthews, Laura
  • Elliott, Gill
  • Newby, Chris
  • Amrani, Yassine
  • Bradding, Peter
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis

Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis

Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats

Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats

Verbundene Objekte